Abstract
Purpose:
To investigate the long-term efficacy of intravitreal conbercept injection in treating idiopathic choroidal neovascularization (CNV).
Methods:
In this longitudinal retrospective cohort study, 27 eyes (27 patients) with idiopathic CNV receiving conbercept intravitreously (0.5 mg/0.05 mL) with 1+PRN regimen were included. Best corrected visual acuity (BCVA) and central retinal thickness (CRT) at the baseline and the end of follow-up were compared, respectively. The number of injections and recurrence time were evaluated.
Results:
Of the 27 patients, 7 were men and 20 were women. Their mean age at diagnosis was 31.37 ± 7.35 (16–46) years. The follow-up period was 44.59 ± 8.60 (27–58) months. The mean initial injection number was 1.22 ± 0.42, and 1.67 ± 1.04 injections were administered throughout the follow-up. Seven patients experienced CNV relapse, with 1 episode in 4 patients, 2 episodes in 2 patients, and 5 episodes in 1 patient. LogMAR BCVA changed from 0.77 ± 0.19 at baseline to 0.09 ± 0.10 at the final visit, and CRT decreased from 343 ± 73.5 μm to 172.41 ± 30.82 μm. Both BCVA improvement and CRT reduction were statistically significant (P < 0.001). No ocular or systemic complications occurred.
Conclusions:
Intravitreal injection of conbercept shows favorable effectiveness in the treatment of idiopathic CNV during a long-term period of follow-up.
Get full access to this article
View all access options for this article.